Вы находитесь на странице: 1из 25


European Network of Paediatric Research

at the European Medicines Agency

Background information

An agency of the European Union

Irmgard Eichler, MD
European Paediatric Regulation
Improve the health of children
• Increase high quality research into medicines for children
• Increase availability of authorised medicines for children
• Increase information on medicines
• Avoid unnecessary studies in children
• Avoid delaying authorisation for adults

Main Pillars of the Regulation:

- the paediatric committee (PDCO)
- the paediatric investigation plan (PIP)

Paediatric Committee (PDCO)

27 Members (plus
including 5 from Approval Committee

2 from Norway, Iceland

3 Patient representatives
3 HealthCare Professionals

1 Chair elected
Paediatric Committee
• Anaesthesiology,
neonatology, cardiology,
immunology, transplantation,
respiratory, ICU,
haematology, oncology,
endocrinology and diabetes,
adolescent medicine,
infectious diseases,
gastroenterology and
nutrition, general paediatrics,
methodology, pharmacology,
pharmacovigilance, vaccines
• Formulation Working Group
• Non-clinical Working Group
• Extrapolation Working Group

What is a PIP (paediatric investigation plan)?

• Details of the measures and timing to demonstrate:

- Quality
- Efficacy Authorisation
- Safety Criteria

• Basis for development and authorisation of a

medicinal product for children
• To be agreed by the PDCO
• Binding on company  compliance check

What is a Waiver?

• EMA Decision waiving the need for paediatric

development of the product in a certain condition
• Can apply to some or all subsets of paediatric population
• List of ‘class’ waivers (conditions)
• Product-specific waivers because of

- Probable lack of efficacy, or safety concern

- Disease/condition occurring only in adult population
- Lack of significant therapeutic benefit
European Paediatric Regulation

Unless an EMA decision on a Paediatric

Investigation Plan or waiver is included,
the validation of a marketing authorisation
application – even for adults only – will be

Introduction and background

Legal basis
European Paediatric Regulation:
“The EMA shall, with the scientific support of the Paediatric
Committee, develop a European network of existing national and
European networks, investigators and centres with specific expertise
in the performance of studies in the paediatric population.”

Introduction and background

• Enpr-EMA is a network of research networks,

investigators and centres with recognised expertise in
performing clinical trials in the paediatric population
• Members perform research with children (newborns to
adolescents), in multiple therapeutic areas, and ranging
from pharmacokinetics to pharmacovigilance

Mission statement

Enpr-EMA will facilitate studies in order to

increase availability of medicinal products
authorised for use in the paediatric population.

Mission statement
This will be achieved by:
• Fostering high quality ethical research on the safety and
effectiveness of medicines for children.
• Efficient inter-network and stakeholder collaboration in order to build
up necessary competences at EU level and to avoid unnecessary
duplication of studies.
• Informing parents, carers, children and young people about clinical
trials and encourage their participation.
• Raising awareness among health care professionals of the need for
clinical trials in all ages of children and supporting their involvement
in such studies.
• Assisting and entering into discussion with ethics committees on
issues relevant to research and clinical trials in children.
Recognition criteria
• Networks to be recognised by quality of paediatric research
• 6 recognition criteria and quality standards for self-assessment
➣ Research experience and ability
➣ Efficiency requirements
➣ Scientific competencies and capacity to provide expert advice

➣ Quality management

➣ Training and educational capacity to build competences

➣ Involvement of patients, parents or their organisations

• Each criterion composed of several sub items

• Set of minimum criteria to be fulfilled
• Self-assessment to updated annually

Breakdown of networks by type and category


Category 1: Networks fulfilling all minimum criteria for membership of Enpr-EMA.

Category 2: Networks potentially fulfilling all minimum criteria – but needing to
clarify some issues before becoming a member of Enpr-EMA.
Category 3: Networks currently not yet fulfilling minimum criteria.

Network for
Research in
PENTI Pediatric Critical

What Enpr-EMA does not do

• fund studies

• act as a CRO and manage studies

• decide on research priorities which

remain the responsibility of
– the Member States
– the Commission through the
Community programmes
– each individual network
Structure - Coordinating Group
Co-chaired by EMA
3 year + elected member

Coordinating EC
Group (20)

Coordinating Group

Role of the Coordinating Group:

➣ to contribute to the short and long-term strategy of the network
➣ to address operational and scientific issues for the network
➣ to agree scientific quality standards
➣ to act as a forum for communication

Main Stakeholders

➣ Pharmaceutical Industry
➣ Patients, parents and patient organisations
➣ National Competent Authorities
➣ Ethics Committees
➣ Medical devices industry
➣ CRO’s
➣ Hospital pharmacists

Interaction with stakeholders

• Annual workshop – open to all stakeholders

• Virtual meetings

• Mail exchange

• Scientific/regulatory conferences


Why should you join Enpr-EMA ?

• increase visibility as potential site(s) for industry-sponsored

studies (requested by PDCO)
• gain access to SMEs for collaboration
• present your centre/network - at a European level
• save resources by sharing work, avoiding duplication

• share skills and expertise with other centres/networks

• shape the future development in paediatric research
• access information on EC framework programmes

What Enpr-EMA can offer to industry

• Pool of patients for inclusion

• Speeding up recruitment
• Expert advice
- treatment options (standard of care)
- paediatric needs
- feasibility of paediatric clinical trials
• Access to academic partners through collaboration with
the SME office at EMA

Enpr-EMA information: http://www.ema.europa.eu


Thank you - Questions ??